Results 241 to 250 of about 913,703 (307)

Serious adverse events following immunization with COVID-19 vaccines in Lebanon: a retrospective analysis of the National Pharmacovigilance Database. [PDF]

BMC Public Health
Karam R, Iskandar K, Watfa M, Zeitoun A.
europepmc   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Development and application of a serious adverse events risk model for concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma. [PDF]

Medicine (Baltimore)
Li J, Liu Q, Qin H.
europepmc   +1 more source

Revisiting the Ethics of Urate‐Lowering Therapy Clinical Trials for Gout Management

Arthritis &Rheumatology, EarlyView.
Lisa K. Stamp, Dien Ho, Nicola Dalbeth
wiley   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Risk factors for death or serious adverse events within 3-month after surgery in frail older persons with hip fractures and development and validation of a risk prediction model: Based on LASSO-logistic regression. [PDF]

BMC Geriatr
Guan Y, Zheng L, Wang Y, Xu X, Zhu Y.
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Prognostic value of heart rate variability for risk of serious adverse events in continuously monitored hospital patients. [PDF]

J Clin Monit Comput
Aagaard N, Olsen MH, Rasmussen OW, Grønbaek KK, Mølgaard J, Haahr-Raunkjaer C, Elvekjaer M, Aasvang EK, Meyhoff CS.   +8 more
europepmc   +1 more source

Predicting serious adverse events or a safety net - Rethinking the role of early warning scores. [PDF]

Resusc Plus
Haegdorens F.
europepmc   +1 more source